Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 16/20 | 0.84 |
| ▸ | AURKA | O14965 | 6/20 | 0.67 |
| ▸ | FLT3 | P36888 | 4/20 | 0.66 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14699430 | 0.91 | ITK (1.00) | ITKAURKAFLT3CCNA2CDK2 | |
| SCHEMBL14699139 | 0.91 | ITK (0.86) | ITKAURKAFLT3CCNA2CDK2 | |
| SCHEMBL14699269 | 0.90 | ITK (0.81) | ITKAURKAFLT3CCNA2CDK2 | |
| SCHEMBL14699151 | 0.89 | ITK (0.79) | ITKAURKAFLT3CCNA2CDK2 | |
| SCHEMBL14699240 | 0.89 | ITK (0.84) | ITKAURKAFLT3CCNA2CDK2 | |
| SCHEMBL14699186 | 0.89 | ITK (0.79) | ITKAURKAFLT3MAP4K1 | |
| SCHEMBL14699252 | 0.88 | ITK (0.86) | ITKAURKAFLT3CCNA2CDK2 | |
| SCHEMBL14699077 | 0.88 | ITK (0.78) | ITKAURKAFLT3CCNA2CDK2 | |
| SCHEMBL14699047 | 0.87 | ITK (0.79) | ITKAURKAFLT3CCNA2CDK2 | |
| SCHEMBL14699260 | 0.87 | ITK (0.79) | ITKAURKAFLT3MAP4K4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742040-B1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| EP-2742040-B1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2742040-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013024011-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024011-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CYP3A43, INSR, CYP2C19 | ITK 1578/4885AURKA 2633/4885FLT3 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.